Taysha Gene Therapies develops AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead efforts have focused on rare neurodevelopmental and neurological disorders, including Rett syndrome, where a one-time gene replacement approach aims to address the underlying genetic cause. The company collaborates closely with academic research partners and targets patient populations with limited or no disease-modifying options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2 | — | -26.9 | — |
| Q3 2025 | 0 | — | -32.7 | — |
| Q4 2025 | 5.5 | — | -27.9 | — |
| Q1 2026 | 0 | — | -42.4 | — |
| Q2 2026 | 0 | -100% | -46.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Jefferson Capital, Inc. (JCAP), Omeros Corporation (OMER), Harmonic Inc. (HLIT), Digital Turbine, Inc. (APPS), D-Market Elektronik Hizmetler ve Ticaret A.S. (HEPS), AIR Global PLC (AIIR)